Hanall Biopharma Co., Ltd. (KRX:009420)

South Korea · Delayed Price · Currency is KRW

54,100

-1,500 (-2.70%)

Aug 7, 2026, 3:30 PM KST

95.31% (1Y)

Market Cap	2.75T +95.5%
Revenue (ttm)	159.06B +12.8%
Net Income	-5.08B
EPS	-100.52
Shares Out	50.79M
PE Ratio	n/a
Forward PE	1,048.80
Dividend	n/a
Ex-Dividend Date	n/a

Volume	267,236
Open	54,600
Previous Close	55,600
Day's Range	52,200 - 55,400
52-Week Range	27,000 - 73,000
Beta	0.88
Analysts	Strong Buy
Price Target	90,000.00 (+66.36%)
Earnings Date	Aug 14, 2026

About Hanall Biopharma

Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascul... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1973

Employees 304

Stock Exchange Korea Stock Exchange

Ticker Symbol 009420

Full Company Profile

Financial Performance

In 2025, Hanall Biopharma's revenue was 155.18 billion, an increase of 11.69% compared to the previous year's 138.94 billion. Losses were -5.56 billion, 208.0% more than in 2024.

Financial Statements

Analyst Summary

According to 6 analysts, the average rating for 009420 stock is "Strong Buy." The 12-month stock price target is ₩90,000, which is an increase of 66.36% from the latest price.

Price Target

₩90,000

(66.36% upside)

Analyst Consensus: Strong Buy

Stock Forecasts